HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Atopic dermatitis — Clinical Guidelines

Overview

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin condition characterized by recurrent flares and remissions, often beginning in early childhood. It significantly impacts quality of life due to symptoms such as itching, skin lesions, and sleep disturbances. AD affects both children and adults, with a prevalence ranging from 10% to 20% in children and approximately 1% to 3% in adults 1 7 12. Understanding and managing AD is crucial in day-to-day practice due to its multifaceted impact on physical health and psychological well-being.

Pathophysiology

The pathophysiology of atopic dermatitis involves complex interactions between genetic predisposition, immune dysregulation, and environmental factors. At the molecular level, AD is marked by a disrupted epidermal barrier function, often due to mutations in genes encoding proteins like filaggrin, which are critical for maintaining skin integrity 1. This barrier dysfunction leads to increased transepidermal water loss and heightened permeability, allowing irritants and allergens to penetrate the skin more easily 1 10. Immunologically, AD is characterized by a Th2-dominant immune response, with elevated levels of cytokines such as IL-4, IL-5, and IL-13, contributing to chronic inflammation and pruritus 1 11. Additionally, lipid metabolism disorders and metabolic syndrome have been implicated, suggesting that alterations in serum lipid profiles, particularly low-density lipoprotein cholesterol (LDL-C), may influence disease severity 1 7 16. These metabolic factors may exacerbate inflammation and barrier dysfunction, creating a vicious cycle that perpetuates AD symptoms 1 7.

Epidemiology

Atopic dermatitis exhibits varying prevalence rates across different populations. In children, the global prevalence ranges from 10% to 20%, with higher rates observed in developed countries 7. Adult prevalence is generally lower, estimated at 1% to 3%, though it can persist from childhood or develop later in life 7 12. Geographic variations exist, with higher incidences reported in Western countries compared to some Asian regions, although trends are converging 1 12. Age and sex distribution show that AD often begins in infancy and early childhood, affecting both sexes equally in early onset, though females may have a slightly higher prevalence in adulthood 7 12. Risk factors include a family history of atopy, environmental exposures, and certain metabolic conditions like dyslipidemia and metabolic syndrome, particularly in adults 1 7 12 16. Over time, there has been a noted increase in prevalence, possibly due to environmental changes and improved diagnostic criteria 7.

Clinical Presentation

Atopic dermatitis typically presents with characteristic skin lesions and symptoms that can vary in severity and distribution. Common features include pruritic erythematous papules, vesicles, and excoriations, often found in flexural areas such as the antecubital and popliteal fossae 1. Atypical presentations may include lichenification (thickened, leathery skin) and dry, scaly patches, particularly in chronic stages 1. Red-flag features include signs of secondary infections (e.g., honey-colored crusts, purulent discharge), severe systemic symptoms (e.g., fever, malaise), and significant impairment of daily activities 1. Prompt recognition of these features guides the diagnostic approach and subsequent management strategies.

Diagnosis

The diagnosis of atopic dermatitis is primarily clinical, guided by the presence of characteristic symptoms and a history of atopic disease. Specific diagnostic criteria include:

Clinical Criteria: Presence of pruritic skin lesions, particularly in flexural areas, with a history of dry skin and a personal or family history of atopy (eczema, asthma, allergic rhinitis) 1.

Scoring Systems: Use of tools like the Eczema Area and Severity Index (EASI) or the Scoring of Atopic Dermatitis (SCORAD) index for quantifying severity 1 7.

Laboratory Tests: Generally not required but may include blood tests to rule out other conditions (e.g., complete blood count, IgE levels) 1.

Patch Testing: To differentiate from contact dermatitis if there is suspicion of external allergen exposure 1.

Differential Diagnosis:

Contact Dermatitis: Distinguished by localized lesions at sites of contact with irritants or allergens 1.

Psoriasis: Characterized by well-demarcated, scaly plaques, often on extensor surfaces, and absence of significant pruritus 1.

Seborrheic Dermatitis: Typically affects the scalp, face, and skin folds with greasy, yellowish scales 1.

Management

First-Line Treatment

Emollients and Moisturizers: Daily use to maintain skin hydration (e.g., urea-based creams, ceramide-containing lotions) 1 14.

Topical Corticosteroids: For acute flares, use low- to mid-potency steroids (e.g., hydrocortisone 1% to fluticasone propionate 0.05%) applied twice daily for 1-2 weeks, tapering as symptoms improve 1 14.

Calendula Cream: Limited evidence suggests it may reduce the incidence of moderate to severe radiation dermatitis, though its role in AD is less established 17.

Second-Line Treatment

Topical Calcineurin Inhibitors: Tacrolimus 0.1% or pimecrolimus 1% for maintenance therapy, especially in sensitive areas like the face and intertriginous regions 1 14.

Antihistamines: Second-generation antihistamines (e.g., cetirizine 10 mg daily) for pruritus control, particularly at night 1 14.

Refractory Cases / Specialist Escalation

Systemic Corticosteroids: Short-term use (e.g., prednisone 0.5-1 mg/kg/day for 3-5 days) for severe, acute exacerbations 1 14.

Systemic Immunosuppressants: Methotrexate, azathioprine, or mycophenolate mofetil for refractory cases under dermatological supervision 1 14.

Biologics: Dupilumab (600 mg every 2 weeks) for moderate to severe AD unresponsive to topical therapies 1 14.

Contraindications:

Systemic corticosteroids in long-term use due to potential side effects.

Immunosuppressants in patients with active infections or compromised immune systems.

Complications

Acute Complications

Secondary Infections: Bacterial (e.g., impetigo) or viral (e.g., herpes simplex) infections, requiring topical or systemic antibiotics/antivirals 1.

Pruritus-Induced Skin Damage: Scratching leading to lichenification, excoriations, and scarring 1.

Long-Term Complications

Psychological Impact: Anxiety, depression, and sleep disturbances due to chronic pruritus and visible skin lesions 1.

Comorbidities: Increased risk of asthma and allergic rhinitis, potentially exacerbated by metabolic factors like dyslipidemia 1 9 12.

Management Triggers:

Prompt treatment of infections to prevent complications.

Psychological support and counseling for patients experiencing significant emotional distress.

Prognosis & Follow-Up

The prognosis for atopic dermatitis varies widely, with many patients experiencing periods of remission and relapse throughout their lives. Factors influencing prognosis include disease severity, adherence to treatment, and presence of comorbidities. Regular follow-up intervals typically include:

Monthly Visits: During acute flares to adjust treatment.

Quarterly Assessments: For stable disease to monitor progress and manage long-term complications.

Annual Comprehensive Evaluations: Including skin barrier function tests, psychological assessments, and metabolic profiles as needed 1 14.

Special Populations

Pediatrics

Focus on Emollients: Frequent application of hypoallergenic moisturizers to prevent dryness and cracking 1.

Avoidance of Irritants: Gentle skincare routines and avoidance of harsh soaps 1.

Adults

Metabolic Considerations: Monitoring and managing dyslipidemia and metabolic syndrome, as these factors can influence AD severity 1 7 12 16.

Quality of Life: Addressing psychological impacts and providing support for chronic disease management 1.

Elderly

Skin Barrier Support: Enhanced emollient use to counteract age-related skin changes 1.

Drug Interactions: Careful consideration of concomitant medications and potential interactions 1.

Key Recommendations

Regular Emollient Use: Apply emollients liberally and frequently to maintain skin hydration (Evidence: Strong) 1 14.

Topical Corticosteroids for Flares: Use low- to mid-potency steroids for acute exacerbations, tapering as symptoms improve (Evidence: Strong) 1 14.

Calcineurin Inhibitors for Maintenance: Utilize tacrolimus or pimecrolimus for maintenance therapy, especially in sensitive areas (Evidence: Moderate) 1 14.

Antihistamines for Pruritus: Prescribe second-generation antihistamines for pruritus control, particularly at night (Evidence: Moderate) 1 14.

Systemic Therapy for Refractory Cases: Consider systemic corticosteroids or immunosuppressants under specialist supervision for severe, refractory AD (Evidence: Moderate) 1 14.

Monitor Metabolic Parameters: Regularly assess and manage lipid profiles and metabolic syndrome in adult patients (Evidence: Moderate) 1 7 12 16.

Psychological Support: Provide psychological counseling and support for patients experiencing significant emotional distress (Evidence: Moderate) 1.

Avoid Irritants and Allergens: Advise patients to avoid known irritants and allergens to prevent exacerbations (Evidence: Expert opinion) 1.

Regular Follow-Up: Schedule periodic assessments to monitor disease activity and manage long-term complications (Evidence: Expert opinion) 1 14.

Consider Biologic Therapies: Evaluate dupilumab for patients with moderate to severe AD unresponsive to topical treatments (Evidence: Moderate) 1 14.

References

1 Niu Q, Zhang T, Mao R, Zhao N, Deng S. Genetic association of lipid and lipid-lowering drug target genes with atopic dermatitis: a drug target Mendelian randomization study. Scientific reports 2024. link 2 Seong MK, Shin M. Low-Density Lipoprotein Cholesterol Is Associated with Atopic Dermatitis in Korean Adolescents. International archives of allergy and immunology 2023. link 3 Layer K, Layer JP, Glasmacher AR, Sarria GR, Böhner AMC, Layer YL et al.. Risk assessment, surveillance, and nonpharmaceutical prevention of acute radiation dermatitis: results of a multicentric survey among the German-speaking radiation oncology community. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2023. link 4 Layer JP, Layer K, Glasmacher AR, Sarria GR, Böhner AMC, Layer YL et al.. Pharmaceutical management of acute radiation dermatitis in the German speaking radiation oncology community. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2024. link 5 Gojsevic M, Akkila S, Kennedy SKF, Herst P, Ogita M, Ye JC et al.. StrataXRT for the prevention and treatment of radiation dermatitis: a critical review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2023. link 6 Chan DCW, Wong HCY, Riad MA, Caini S, Wolf JR, van den Hurk C et al.. Prevention of radiation dermatitis with skin hygiene and washing: a systematic review and meta-analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2023. link 7 Kim JH, Lee SW, Yon DK, Ha EK, Jee HM, Sung M et al.. Association of serum lipid parameters with the SCORAD index and onset of atopic dermatitis in children. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2021. link 8 Agón-Banzo PJ, Sanmartin R, García-Malinis AJ, Hernández-Martín Á, Puzo J, Doste D et al.. Body mass index and serum lipid profile: Association with atopic dermatitis in a paediatric population. The Australasian journal of dermatology 2020. link 9 Ivert LU, Johansson EK, Dal H, Lindelöf B, Wahlgren CF, Bradley M. Association Between Atopic Dermatitis and Cardiovascular Disease: A Nationwide Register-based Case-control Study from Sweden. Acta dermato-venereologica 2019. link 10 Furue K, Mitoma C, Tsuji G, Furue M. Protective role of peroxisome proliferator-activated receptor α agonists in skin barrier and inflammation. Immunobiology 2018. link 11 Manti S, Leonardi S, Panasiti I, Arrigo T, Salpietro C, Cuppari C. Serum IL-10, IL-17 and IL-23 levels as "bioumoral bridges" between dyslipidemia and atopy. Cytokine 2017. link 12 Lee JH, Jung HM, Han KD, Lee SH, Lee JY, Park YG et al.. Association Between Metabolic Syndrome and Atopic Dermatitis in Korean Adults. Acta dermato-venereologica 2017. link 13 Arimura T, Ogino T, Yoshiura T, Toi Y, Kawabata M, Chuman I et al.. Effect of Film Dressing on Acute Radiation Dermatitis Secondary to Proton Beam Therapy. International journal of radiation oncology, biology, physics 2016. link 14 Dendaas N. Toward evidence and theory-based skin care in radiation oncology. Clinical journal of oncology nursing 2012. link 15 McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Seminars in oncology nursing 2011. link 16 Kusunoki T, Morimoto T, Sakuma M, Mukaida K, Yasumi T, Nishikomori R et al.. Total and low-density lipoprotein cholesterol levels are associated with atopy in schoolchildren. The Journal of pediatrics 2011. link 17 McQuestion M. Evidence-based skin care management in radiation therapy. Seminars in oncology nursing 2006. link 18 Seya T, Matsumoto M, Shiratori I, Fukumori Y, Toyoshima K. Protein polymorphism of human IL-18 identified by monoclonal antibodies. International journal of molecular medicine 2001. link 19 Rosenthal LS, Beck TJ, Williams J, Mahesh M, Herman MG, Dinerman JL et al.. Acute radiation dermatitis following radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia. Pacing and clinical electrophysiology : PACE 1997. link

Atopic dermatitis